Mergers Partnerships & Acquisitions

April 24, 2020

M&A

October 24, 2018
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam's Thirty Year Journey to First Approval

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

[vc_row][vc_column][vc_column_text]   In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
August 10, 2018
Democratising DNA: 23andMe & GSK Collaboration Raises Privacy & Data Quality Concerns - Can Blockchain Offer a Disruptive Solution?

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

[vc_row][vc_column][vc_column_text] Personal genomics company 23andMe recently entered a four-year $500M collaborative agreement with major pharmaceutical company GlaxoSmithKline. The deal gives GSK access to the genetic data […]
March 27, 2018

All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation

[vc_row][vc_column][vc_column_text] Oxford Nanopore recently announced that it has attracted a further £100M in funding. The latest investment round values Oxford Nanopore at £1.5B, with Singapore-based GIC, […]
March 8, 2018
Charles River Laboratories M&A Activity Analysis: a Differentiated Strategy Delivering Results

Charles River Laboratories M&A Activity Analysis: A Differentiated Strategy Delivering Results

[vc_row][vc_column][vc_column_text] From its early days as one the first suppliers of animal models for research in 1947, Charles River Laboratories (CRL) has developed into a brand […]
October 16, 2017
Evotec Invests €15m in Exscientia in Latest Partnership between Big Pharma & Artificial Intelligence

Evotec Invests €15m in Exscientia in Latest Partnership between Big Pharma & Artificial Intelligence-Driven Drug Discovery

[vc_row][vc_column][vc_column_text] German pharmaceutical company Evotec has expanded its partnership with Scottish artificial intelligence drug design pioneers Exscientia, investing a further €15m in exchange for a minority […]
August 31, 2017
The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies

The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies

[vc_row][vc_column][vc_column_text] Gilead Sciences has ended its M&A moratorium with an $11.9B all-cash acquisition of CAR-T Cell Therapy pioneers Kite Pharma. Kite’s leading drug Axi-Cel is expected […]
May 23, 2017
Thermo Fisher Continues Vertical Integration with $7.2B Acquisition of CDMO Patheon

Thermo Fisher Continues Vertical Integration with $7.2B Acquisition of CDMO Patheon

[vc_row][vc_column][vc_column_text] Dutch Contract Development & Manufacturing Organisation Patheon has been acquired by Thermo Fisher Scientific in a $7.2B deal. The acquisition, which includes the assumption of […]
April 12, 2017
GE Healthcare Adds to Its Cell Therapy Portfolio with Acquisition of Asymptote

GE Healthcare Adds to Its Cell Therapy Portfolio with Acquisition of Asymptote

[vc_row][vc_column][vc_column_text]GE Healthcare recently announced the acquisition of British cryogenic processing company Asymptote for an undisclosed price, strengthening its cell therapy portfolio with technologies designed to enable […]
Contact Us